84 related articles for article (PubMed ID: 25261662)
21. A case-case study comparing the usefulness of serum trace elements (Cu, Zn and Se) and tumor markers (CEA, SCC and SLX) in non-small cell lung cancer patients.
Oyama T; Kawamoto T; Matsuno K; Osaki T; Matsumoto A; Isse T; Nakata S; Ozaki S; Sugaya M; Yasuda M; Yamashita T; Takenoyama M; Sugio K; Yasumoto K
Anticancer Res; 2003; 23(1B):605-12. PubMed ID: 12680155
[TBL] [Abstract][Full Text] [Related]
22. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
23. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.
Dediu M; Crisan E; Radut M; Tarlea A; Median D; Alexandru A; Vremes G; Gal C
Lung Cancer; 2009 Feb; 63(2):271-6. PubMed ID: 18565617
[TBL] [Abstract][Full Text] [Related]
24. Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer.
Yamaguchi M; Toyokawa G; Ohba T; Sasaki T; Kometani T; Hamatake M; Hirai F; Taguchi K; Yamanaka T; Seto T; Takenoyama M; Sugio K; Ichinose Y
Ann Thorac Surg; 2013 Nov; 96(5):1783-9. PubMed ID: 23998404
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery.
Ahn HK; Choi YL; Han JH; Ahn YC; Kim K; Kim J; Shim YM; Um SW; Kim H; Kwon OJ; Sun JM; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2013 Mar; 79(3):300-6. PubMed ID: 23261144
[TBL] [Abstract][Full Text] [Related]
26. Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach.
Parlak C; Mertsoylu H; Güler OC; Onal C; Topkan E
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):885-91. PubMed ID: 24495594
[TBL] [Abstract][Full Text] [Related]
27. Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer.
Sen F; Saglam EK; Toker A; Dilege S; Kizir A; Oral EN; Saip P; Sakallioglu B; Topuz E; Aydiner A
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1497-505. PubMed ID: 21499895
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
Rades D; Setter C; Dahl O; Schild SE; Noack F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
[TBL] [Abstract][Full Text] [Related]
31. Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy.
Choi HS; Jeong BK; Jeong H; Lee YH; Ha IB; Song JH; Kang KM
Radiat Oncol; 2017 Jul; 12(1):122. PubMed ID: 28732516
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Tokuda Y; Takigawa N; Kozuki T; Kamei H; Bessho A; Tada A; Hotta K; Katsui K; Kanazawa S; Tanimoto M; Kiura K
Acta Oncol; 2012 Apr; 51(4):537-40. PubMed ID: 22085375
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
Casal Rubio J; Fírvida-Pérez JL; Lázaro-Quintela M; Barón-Duarte FJ; Alonso-Jáudenes G; Santomé L; Afonso-Afonso FJ; Amenedo M; Huidobro G; Campos-Balea B; López-Vázquez MD; Vázquez S
Cancer Chemother Pharmacol; 2014 Mar; 73(3):451-7. PubMed ID: 24352251
[TBL] [Abstract][Full Text] [Related]
36. Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis.
Bar J; Ng D; Moretto P; Goss GD; Sun A; Macrae R; Laurie SA; Leighl N; Nicholas G
Clin Lung Cancer; 2013 Mar; 14(2):200-4. PubMed ID: 22868221
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy.
Mitsuyoshi T; Matsuo Y; Itou H; Shintani T; Iizuka Y; Kim YH; Mizowaki T
J Radiat Res; 2018 Jan; 59(1):50-57. PubMed ID: 29182777
[TBL] [Abstract][Full Text] [Related]
38. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
39. Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response.
Fujii M; Hotta K; Takigawa N; Hisamoto A; Ichihara E; Tabata M; Tanimoto M; Kiura K
Lung Cancer; 2012 Oct; 78(1):107-11. PubMed ID: 22858447
[TBL] [Abstract][Full Text] [Related]
40. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.
Xu YH; Lu S
Eur J Surg Oncol; 2014 Mar; 40(3):311-7. PubMed ID: 24332948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
